Trading in Noven Common Stock Halted; FDA Advisory Committee Meeting Today on Daytrana(TM).

MIAMI -- Noven Pharmaceuticals, Inc. (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :NOVN) announced that NASDAQ has halted trading of Noven common stock effective this morning, December 2, 2005. The Psychopharmacologic Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA FDA
abbr.
Food and Drug Administration

FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration. ) meets today to review and discuss the amended New Drug Application for Daytrana(TM) (methylphenidate methylphenidate /meth·yl·phen·i·date/ (meth?il-fen´i-dat) a central stimulant, used in the form of the hydrochloride salt in the treatment of attention-deficit in children and narcolepsy. transdermal system).

Daytrana(TM), licensed globally to Shire plc, is an investigational transdermal patch designed for once-daily use to treat attention deficit hyperactivity disorder attention deficit hyperactivity disorder (ADHD), formerly called hyperkinesis or minimal brain dysfunction, a chronic, neurologically based syndrome characterized by any or all of three types of behavior: hyperactivity, distractibility, and impulsivity. (ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition

Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or ) in children aged 6 to 12 years.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are sold in over 30 countries, and a range of new patches are being developed in collaboration with Shire plc, Novartis Pharma AG, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. See http://www.noven.com for additional information.

COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	Business Wire
Geographic Code:	1USA
Date:	Dec 2, 2005
Words:	146
Previous Article:	InforSense Initiates Annual 'Open House': Presentations by Customers, Including GlaxoSmithKline and Windber Research Institute, Showcase ROI for...
Next Article:	The EU's New Regulatory Framework (NRF) Has Been Supplemented by the eEurope 2005 and i2010 Initiatives Which Encourage Development in the Broadband...
Topics:	Attention deficit hyperactivity disorder Attention-deficit hyperactivity Drug approval Drugs Pharmaceutical industry Stocks Transdermal drug delivery systems Transdermal medication

Related Articles
Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26.
Getting information about the FDA and its activities. (FDA Contacts).(Brief Article)
Developmental Methylphenidate Patch Scheduled for FDA Advisory Committee Review.
Noven Announces Availability of Briefing Documents for Daytrana(TM) Advisory Committee Meeting.
Noven Announces Results of Daytrana(TM) Advisory Committee Meeting.
Noven to Commence Manufacture Of Daytrana(TM) Methylphenidate Transdermal System.
FDA Issues Approvable Letter for Daytrana(TM) Methylphenidate Transdermal System.
SHIRE GETS FDA APPROVABLE LETTER FOR DAYTRANA FOR ADHD.
Noven Announces FDA Approval of Daytrana(TM) Methylphenidate Transdermal System.
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System.